Navigation Links
Hayes, Inc. Releases Guide to BRCA1 and BRCA2 Genetic Testing
Date:5/14/2010

Inappropriate referrals for BRCA1/2 testing drives costs and creates undue anxiety for women.

(PRWEB) May 14, 2010 -- A guide to BRCA1 and BRCA2 genetic testing has been released by Hayes, Inc. This comprehensive resource is designed to equip physicians and other healthcare professionals who are not trained in genetics with independent, evidence-based information to help them understand the complexities of BRCA1/2 gene testing.

According to the American Cancer Society, breast cancer is the most common cancer among American women, except for skin cancers. Women who carry a change in one of the breast cancer susceptibility genes, BRCA1 or BRCA2, have an increased risk of breast and ovarian cancer. Changes in the BRCA1/2 genes can occur in any racial or ethnic group, although in the U.S. they are found most often in Jewish women of Ashkenazi (Eastern Europe) origin. Increasing numbers of women are seeking information concerning their risk of developing breast or ovarian cancer, often with heightened anxiety that has been fueled by direct-to-consumer advertising and information in the social media.

“Knowledge of the genetic basis of a disease has the potential to revolutionize personal healthcare,” says Dr. Diane Allingham-Hawkins, Director, Hayes Genetic Test Evaluation Program. “Unfortunately, however, there is a great deal of misuse of expensive genetic tests due to a lack of understanding of the true clinical utility of these tests. In reality, only 5% of cases of breast or ovarian cancer are caused by these hereditary genetic changes.”

However, the combination of anxiety regarding cancer risk, direct-to-consumer advertising and publicity about the tests, and lack of physician knowledge in the field of genetics has led to inappropriate referrals for women seeing BRCA1 and BRCA2 genetic testing.

“We understand that some of the reasons for these inappropriate referrals are the physician’s concern about upsetting a patient by saying ‘no’ to her request, even though she doesn’t meet the guidelines for testing,” says Dr. Allingham-Hawkins. “However, test results will not provide useful information about cancer risk unless the woman meets these guidelines, and can lead to undue worry without providing any health benefit. In addition, the cost of these tests alone can be greater than $3500, with the recommended genetic counseling adding even more.”

Written in a style that can be understood by both the clinician and non-clinician, the Hayes Guide scrutinizes nearly 300 scientific and clinical publications to provide unbiased information and recommendations regarding BRCA1/2 testing in different patient populations. Included is an in-depth analysis describing each of these tests, with special attention focused on the clinical validity, analytical validity, clinical utility, cost, major payer coverage policies, genetic counseling recommendations, and what the future holds for genetic testing for hereditary breast and ovarian cancer. Generally, access to Hayes genetic test evaluations requires a password-protected subscription to the Hayes Knowledge Center. However, recognizing the importance of this information, Hayes is releasing this special volume for a one-time fee. Click here for more information.

Hayes, Inc. is an independent health technology research and consulting company dedicated to promoting better health outcomes through the use of evidence. The Hayes Genetic Test Evaluation (GTE) program cuts through the “genohype” to the scientific proof regarding the appropriate use of genetic and genomic tests in clinical practice. Currently, there are more than 2000 genetic and genomic tests for inherited and acquired disorders on the market in the United States. With an annual growth rate of 25%, this rapidly growing field has created challenges for healthcare professionals to respond quickly and appropriately to issues related to these tests. Hayes GTE conducts evidence-based assessments with clear, concise conclusions across a range of conditions and applications, including hereditary, cardiovascular, neurological, and developmental disorders, as well as oncology. www.hayesinc.com

Hayes, Inc.: Karen Matthias at 215-855-0615 or kmatthias(at)hayesinc(dot)com

###


Read the full story at http://www.prweb.com/releases/2010/05/prweb4000094.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Hayes, Inc. Technology Prognosis Team Tracks First-of-a-Kind Technologies
2. CerMedia Releases MarinePure High Surface Area Media for Aquatic Biofiltration
3. Premier Literacy Releases Version 12 of the Most Comprehensive Offering of Literacy Tools Available Today
4. Loadstar Sensors Releases LoadVUE-1000 Load Cell Software with Logging, Plotting and Alerting features
5. San Francisco Plastic Surgeon Releases Plastic Surgery Patient Recovery Blog
6. Wyatt Matas & Associates Releases White Paper on Future Home Healthcare Business Model
7. LeveragePoint Releases Complete Online Value Management Solution
8. “You Are Very Pretty”, Says Myeexpert As It Releases A Book, Poetic Expressions, Dedicated To The Beauty of Women.
9. STC Releases iPhone Application to Track Your Immunization Records – MyIR™
10. ASTRO releases SBRT for lung cancer report
11. American Human Development Project Releases 'A Century Apart,' Revealing Alarming Disparities in Well-Being Among U.S. Racial and Ethnic Groups
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: